论文部分内容阅读
目的:探讨氯沙坦对原发性高血压伴左心室肥厚患者左心室结构及血清MMP-9的影响。方法:86例原发性高血压伴左心室肥厚患者分为氯沙坦治疗组(n=46)和对照组(n=40)。在治疗前及治疗后8w,测定收缩压和舒张压,用彩色多普勒超声诊断仪测量舒张期左心室后壁厚度(PWT),舒张期室间隔厚度(IVST),左心室舒张末内径(LVID),并计算左室重量指数(LVMI)以判定左心室肥厚程度,另外,采用酶联免疫吸附法(ELISA)检测血清MMP-9。结果:治疗8w后,两组患者的收缩压、舒张压、LVMI值、血清MMP-9均较治疗前低(P<0.01或P<0.05),且氯沙坦治疗组患者的收缩压、舒张压、LVMI值、血清MMP-9较对照组低(P<0.01或P<0.05)。结论:氯沙坦能降低原发性高血压血压、逆转左心室肥厚,并且能降低血清MMP-9表达。
Objective: To investigate the effect of losartan on left ventricular structure and serum MMP-9 in patients with essential hypertension and left ventricular hypertrophy. Methods: Eighty-six patients with primary hypertension and left ventricular hypertrophy were divided into losartan treatment group (n = 46) and control group (n = 40). Systolic blood pressure and diastolic blood pressure were measured before treatment and 8 weeks after treatment. Left ventricular posterior wall thickness (PWT), diastolic ventricular septal thickness (IVST) and left ventricular end diastolic diameter (diastolic diameter) were measured by color Doppler sonography. LVID) were measured. Left ventricular mass index (LVMI) was calculated to determine left ventricular hypertrophy. In addition, serum MMP-9 was detected by enzyme-linked immunosorbent assay (ELISA). Results: After 8 weeks of treatment, the systolic blood pressure, diastolic blood pressure, LVMI, serum MMP-9 in both groups were significantly lower than those before treatment (P <0.01 or P <0.05) LVMI and serum MMP-9 were lower than those in the control group (P <0.01 or P <0.05). Conclusion: Losartan can reduce the blood pressure of essential hypertension, reverse the left ventricular hypertrophy, and can reduce the serum level of MMP-9.